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In this issue, Matsumoto et al. (1) report that histamine
exocytosed from brain mast cells (MCs) after activation by
antigenic cross-linking of the high affinity IgE receptor
 
(Fc
 
 
 
RI) acts via Hl receptors at the hypothalamus to elicit
corticotropin-releasing factor (CRF). These findings reveal
a homeostatic response to a pathobiologic event in the
dog. Conversely, CRF can also be proinflammatory by
mediating activation of tissue MCs (2). This action is im-
plicated in the acute immobilization stress response of the
rat, in which degranulation of brain MCs is associated with
a histamine H2 receptor–mediated increase in permeability
of the blood–brain barrier (3). These models remind us
that the inflammatory response is homeostatic in principle
and pathobiologic only when the same pathways lead to an
outcome that is more detrimental than beneficial to the
host. Thus, the elegant demonstration that experimental
allergic encephalomyelitis in the mouse can be MC depen-
dent (4) invites readers to think of the contribution of the
MC to dysfunction of the blood–brain barrier rather than
its homeostatic hypothalamic-pituitary-adrenal signal func-
tion. As the documented role of the MC expands beyond
recognition of its contribution to adverse local and sys-
temic allergic responses, it is pertinent to review its de-
velopment, remarkable proinflammatory armamentarium,
and participation in an evolving number of models of
pathobiologic processes.
Although MCs are derived, like other leukocytes, from
hematopoietic stem cells (5), they do not mature before ex-
iting the bone marrow and circulate as committed progeni-
tors. These progenitors complete their maturation with
concomitant phenotypic diversity after moving into diverse
peripheral tissues (Fig. 1). Their presence in these periph-
eral tissues depends on the action of their cell surface ty-
rosine kinase, c-
 
kit
 
, and its ligand, stem cell factor (SCF).
The circulating progenitors have been isolated from human
blood as c-
 
kit
 
 
 
CD34
 
 
 
CD13
 
 
 
Fc
 
 
 
RI
 
  
 
cells. This popula-
tion contains both committed progenitors and cells that are
bipotent, that is, able to differentiate into either MCs or
monocytes (6). Progenitors also have been identified in the
blood of 15.5-d-old fetal mice, where they represent an
usually high proportion (
 
 
 
2.5%) of the mononuclear cells
at this point in development (7). These cells are poorly
granulated, express high levels of c-
 
kit,
 
 low levels of Thy-1,
and no Fc
 
 
 
RI and show no capacity to differentiate into
any other cell type. Thus, these cells are committed MC
progenitors. In the adult mouse, the mucosa of the intes-
tine contains the largest peripheral pool of these committed
progenitors (8). However, in the absence of inflammation,
these cells do not develop into mature MCs. The rejection
of many intestinal parasites requires the intestinal hyperpla-
sia of a differentiated MC population (9) and therefore, the
large reservoir of undifferentiated but committed progeni-
tors provides homeostasis in an environment in which in-
testinal parasitism is a constant threat.
 
The progenitors represent a single lineage that gives rise
to distinct phenotypes after moving into different tissues
and under different situations within a tissue (10–12). In the
initial identification of MCs based on fixation properties
and histochemical stains, two prominent phenotypes were
recognized in rodents that reflect the biochemical proper-
ties of these cells in connective tissues or intestinal mucosa
(13) and gave rise to the trivial nomenclature of connective
tissue MCs (CTMCs) and mucosal MCs (MMCs). We now
recognize phenotypic differences in the protease expression
profile even within these anatomically defined cell popula-
tions of the mouse (10–12). Their histochemical differences
are associated with heparin glycosaminoglycan-rich pro-
teoglycans for CTMCs compared with mono- and disul-
fated chondroitin sulfate glycosaminoglycans linked to the
same peptide core in MMCs (14, 15). Human MCs do not
provide these histochemical distinctions, and human MCs
obtained from dispersed lung exhibit both heparin and
chondroitin sulfate proteoglycans (16). An important dis-
tinction for the MMCs of both mouse and human is their T
cell dependence for these cells are lacking in athymic mice
and in humans with acquired immunodeficiency disease
(17, 18). In both settings, CTMCs are present in the sub-
mucosa, contrasting their constitutive appearance with the
reactive character of MMCs. These two phenotypes of
MCs also have other biochemical differences, with the
MMC being low in histamine and high in activation-elic-
ited cysteinyl leukotriene (cys-LT) production and the
CTMC having a high histamine content and generating the
 
prostanoid, prostaglandin (PG)D
 
2
 
, in marked preference to
cys-LT (19). These distinctions may be pertinent to the un-
derstanding of animal models, but the available data for T
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cell–determined phenotypic MC changes are best defined
for the intestine and are available only by implication for
other mucosal surfaces.
In the mouse, 12 different proteases are stored along
with the amines, histamine and serotonin, in the secretory
granules as a complex with different proteoglycans that
share the same peptide core (for a review, see reference
20). Distinct functions have been recognized for some of
the proteases. Mouse MC protease (mMCP)-5, a chymase
(chymotryptic-like secretory granule protease), has been
deleted directly by targeted disruption of the gene and in-
directly by targeted disruption of the N-sulfotransferase-2
gene needed for the production of heparin glycosami-
noglycan (21–23). In both cases, there was coincident loss
of mMC-carboxypeptidase A expression. In both instances,
the cutaneous MCs representing the CTMC phenotype
were abnormally small with poor granule morphology,
whereas the 
 
Trichinella spiralis
 
–elicited MMCs were robust
and of normal phenotype. These findings emphasize that
the tissue dictates the phenotypic diversity for the single
MC lineage. There were also severe developmental abnor-
malities in several organs such as the eyes. As a develop-
mental abnormality of the eye, for example, is not present
in the W/Wv strain, either the short-lived progenitors in
the bone marrow of W/Wv mice are sufficient for normal
development or the phenotype results from an imbalance
of proteases created by the disruption. Recombinant
mouse tryptase mMCP-6, recombinant human 
 
 
 
I tryptase,
and a tryptase preparation isolated from human MCs all
cause neutrophil accumulation in vivo, whereas recombi-
nant mMCP-7 causes eosinophil accumulation in vivo and
human MC chymase induces the accumulation of neutro-
phils and other leukocytes in vivo (24–27). Furthermore,
the directed migration of neutrophils into the lung by re-
combinant human 
 
 
 
I tryptase protects the W/Wv mouse
against pulmonary infection by 
 
Klebsiella pneumoniae
 
 (25).
 
The mouse tryptase mMCP-7 cleaves fibrinogen in vivo
and blocks its function; this action could limit the func-
tions of fibrinogen in MC-mediated reactions (28). The
mouse jejunal MMC–specific chymase mMCP-1 is impor-
tant in the rejection of 
 
T. spiralis
 
, as mice rendered defi-
cient in mMCP-1 by targeted disruption of the gene have
an impaired ability to expel this nematode (29). Other
studies with gene-disrupted mice have confirmed the asso-
ciation of the T cell cytokines with the appearance of the
MMCs and rejection of various helminths (30, 31). In a
model of neoplasia, the CTMC proteases mMCP-4 (chy-
mase family) and mMCP-6 were implicated in the MC-
mediated upregulation of angiogenesis (32). Other possible
functions not yet proven in vivo include cleavage of angio-
tensin I to angiotensin II, stimulation of mucus secretion,
activation of metalloproteases, and activation of protease-
activated receptors (20).
Whereas the secretory granule amines, proteases, and
proteoglycans are stored for immediate release by exocyto-
sis, the perinuclear membrane and endoplasmic reticulum
respond to the same activation signal with the release of
arachidonic acid for processing into eicosanoids. For the
MC, PGD
 
2
 
 is the dominant prostanoid product, and the
cys-LT, LTC
 
4
 
, dominates over the dihydroxy leukotriene,
LTB
 
4
 
. In mice with a targeted disruption of the gene for
LTC
 
4
 
 synthase (LTC
 
4
 
S), which provides LTC
 
4
 
, the parent
of all receptor-active cys-LTs, the augmented vascular per-
meability causing edema in innate and adaptive immune
inflammation is attenuated (33). Both zymosan-elicited,
monocyte/macrophage-mediated intraperitoneal plasma
influx and IgE/antigen-initiated MC-dependent ear edema
were reduced by one half. The latter is noteworthy be-
cause cutaneous MCs, exemplifying the CTMC pheno-
type, were projected from studies with dispersed tissue
MCs to be prostanoid-producing rather than cys-LT–pro-
ducing phenotypes (19). Disruption of the classical PGD
 
2
Figure 1. MC development and diversity.
MC lineage progenitors arise in the bone
marrow, circulate through the vasculature,
and move into tissues to complete their de-
velopment. In skin and connective tissues of
mice, mature MCs present different protease
phenotypes within their secretory granules
in different tissues. In mucosal tissues of
mice, MCs remain as committed progenitors
until acted on by T cell–derived cytokines. 
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receptor, DP, confirmed the action of PGD
 
2
 
 on the mi-
crovasculature and airway smooth muscle in an aerosol an-
tigen challenge of a sensitized mouse (34). The subsequent
recognition by in vitro assays that PGD
 
2
 
 is also a ligand for
a chemokine-like receptor (termed CRTH2) on human T
cells, basophils, and eosinophils (35) provides a candidate
feedback pathway for the Th2/MC duo in allergic inflam-
mation.
A direct role of MC-derived cytokines in vivo has been
demonstrated only for TNF-
 
 
 
. Mice that either have a tar-
geted disruption of the TNF-
 
 
 
 gene or are MC deficient
due to a functional inactivation of their c-
 
kit
 
 (W/Wv) are
highly susceptible to death after cecal ligation and puncture,
compared with their normal littermates (36, 37). W/Wv
mice can be protected by reconstitution of their peritoneal
MC population through the adoptive transfer of immature
MCs derived in vitro from the bone marrow of their nor-
mal littermates, in combination with the cytoprotective and
mitogenic MC effects of administered recombinant stem
cell factor. The serosal cavity MCs implicated in this innate
host resistance are of the CTMC phenotype. In contrast,
the MMCs developed in a T cell–dependent manner from
intestinal progenitors are effective in the expulsion of adult
 
T. spiralis
 
 in mice with a disruption of their TNF-
 
 
 
 recep-
tor gene (30). Cutaneous MC-derived TNF-
 
 
 
 also induces
endothelial leukocyte adhesion molecule-1 in humans (38),
and its role in the mouse cecal ligation and puncture model
is attributed to neutrophil recruitment (36, 37). In this con-
text, a proinflammatory function is clearly homeostatic.
The observation that ischemia-reperfusion injury of a
hind limb of a mouse can be associated with remote pul-
monary injury implies a mediator signal. That the lung is
spared the injury, neutrophil extravasation, and edema by
the lack of MCs in the W/Wv mouse (39) or by deficiency
of the fifth complement component in an otherwise normal
mouse (40) links two proinflammatory pathways, comple-
ment and MCs, but does not define their order. Of equal
note are the findings that the W/Wv mouse is protected
not only against the remote site injury, but also partially
against the permeability enhancement, PMN extravasation,
and myofibril disruption of the targeted hind limb (41).
In contrast to the in vivo proinflammatory actions of
MCs that form the basis of our limited knowledge of their
“diverse roles” (Fig. 2), Matsumoto et al. (1) suggest that
MCs in the central nervous system may participate in the
counter-regulation of an immune inflammatory response
through interactions with the hypothalamic-pituitary-adre-
nal axis. In this study, the dogs were passively sensitized by
the administration of IgE either intracerebroventricularly
or intravenously and were challenged with specific antigen,
either intracerebroventricularly or intravenously, resulting
in cortisol release from the adrenal glands. The effect could
be mimicked by intracerebroventricular injection of the
MC secretagogue compound 48/80 and was blocked by
corticotropin-releasing hormone (CRH) antibodies or his-
tamine H1-blockers. Because glucocorticoids can be used
to downmodulate immune reactions, Matsumoto et al.
suggest that this pathway is an immunomodulator in which
Figure 2. MC function. Mature cells release preformed mediators, proteases, and vasoactive amines; vasoactive de novo–derived arachidonic acid me-
tabolites, LTC4 and PGD2; and activation-induced gene products, e.g., TNF- . These mediators have pleiotropic and even redundant effects on various
tissues such as smooth muscle, leukocytes, and hypothalamic neurons (indicated by box in top right). Of note, the interaction between neurons and MCs
can result in activation of MCs via CRF with resultant inflammation and disruption of the blood–brain barrier or release of adrenal-derived glucocorti-
coids with the potential downmodulation of an inflammatory response. This scheme is based primarily on studies done in rats and mice with the antiin-
flammatory production of cortisol derived from the dog. 
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the MCs act as the switch, detecting high levels of systemic
antigen and activating the hypothalamic-pituitary-adrenal
axis to prevent anaphylaxis.
The armamentarium and distribution of tissue MCs fore-
tells a role for these cells in host integrity and disease that
has not yet been realized. The reasons relate to their biol-
ogy. Mature MCs do not circulate like cells of most he-
matopoietic lineages and do not dominate a single organ
like parenchymal cells. The tissue-based progenitors cannot
yet be recognized except by limiting dilution of dispersed
tissue cells with culture-driven lineage identification. Their
diverse differentiated tissue phenotypes are defined reason-
ably well for the secretory granule compartment for the
mouse, but only minimally for humans and rats. Further-
more, the functions of these proteases, which dominate the
total protein of this cell, are largely unknown, especially in
vivo. The ability to appreciate their capacity for gene in-
duction or eicosanoid generating preference in situ is lim-
ited by issues of identification with product quantitation.
Even a presumptive straightforward systemic anaphylactic
response is severely species related, based in part on the an-
atomic location of the targeted MCs. Humans experience
laryngeal edema or acute emphysema with hypoxia or en-
counter a direct cardiovascular demise without antecedent
hypoxia (42). Only the guinea pig resembles the human
with fatal acute emphysema and no other species is known
to have laryngeal edema. The dog experiences
 
 
 
a hypo-
volemic death due to pooling in the liver because of a MC
distribution that attenuates outflow. Nonetheless, progress
in understanding the biology of the MC can be derived
from models that use the MC-deficient W/Wv strain, mice
with targeted disruptions of MC–selective genes (e.g.,
mMCP-1
 
 
 
/
 
 
 
, mMCP-5
 
 
 
/
 
 
 
), and mice with targeted dis-
ruption of genes expressed nonexclusively in MC (e.g.,
LTC
 
4
 
S
 
 
 
/
 
 
 
). After calibration of MC-selective responses
such as IgE-mediated anaphylaxis for CTMCs and hel-
minth infection for MMCs, more complex models can be
approached. As the developmental and functional biology
of the MC continues to unfold, the role of this cell in sur-
rogate models of human diseases and its direct assessment in
clinical settings will address the mysteries of its nature.
 
Supported by grants HL36110-16, AI31599-10, AI07306, and
HL63284-02 from the National Institutes of Health.
 
Submitted: 30 May 2001
Accepted: 1 June 2001
 
References
 
1. Matsumoto, I., Y. Inoue, T. Shimada, and T. Aikama. 2001.
Brain mast cells act as an immune gate to the hypothalamic-
pituitary-adrenal axis in dogs. 
 
J. Exp. Med
 
. 194:71–78.
2. Singh, L.K., W. Boucher, X. Pang, R. Letourneau, D. Sere-
takis, M. Green, and T.C. Theoharides. 1999.
 
 
 
Potent mast
cell degranulation and vascular permeability triggered by uro-
cortin through activation of corticotropin-releasing hormone
receptors. 
 
J. Pharmacol. Exp. Ther. 
 
288:1349–1356.
 
3. Esposito, P., D. Gheorghe, K. Kandere, X. Pang, R. Con-
nolly, S. Jacobson, and T.C. Theoharides. 2001. Acute stress
increases permeability of the blood
 
¯
 
brain-barrier through ac-
tivation of brain mast cells. 
 
Brain Res. 
 
888:117–127.
4. Secor, V.H., W.E. Secor, C.-A. Gutekunst, and M.A.
Brown. 2000. Mast cells are essential for early onset and se-
vere disease in a murine model of multiple sclerosis. 
 
J. Exp.
Med.
 
 191:813–822.
5. Kitamura, Y., S. Go, and K. Hatanaka.1978. Decrease of
mast cells in W/Wv mice and their increase by bone marrow
transplantation. 
 
Blood.
 
 52:447–452.
6. Kirshenbaum, A.S., J.P. Goff, T. Semere, B. Foster, L.M.
Scott, and D.D. Metcalfe. 1999. Demonstration that human
mast cells arise from a progenitor cell population that
is CD34(
 
 
 
), c-kit(
 
 
 
), and expresses aminopeptidase N
(CD13). 
 
Blood.
 
 94:2333–2342.
7. Rodewald, H.R., M. Dessing, A.M. Dvorak, and S.J. Galli.
1996. Identification of a committed precursor for the mast
cell lineage. 
 
Science.
 
 271:818–822.
8. Guy-Grand, D., M. Dy, G. Luffau, and P. Vassalli. 1984. Gut
mucosal mast cells. Origin, traffic, and differentiation. 
 
J. Exp.
Med
 
. 160:12–28.
9. Urban, J.F. Jr., L. Schopf, S.C. Morris, T. Orekhova, K.B.
Madden, C.J. Betts, H.R. Gamble, C. Byrd, D. Donaldson,
K. Else, and F.D. Finkelman. 2000. Stat6 signaling promotes
protective immunity against 
 
Trichinella spiralis
 
 through a mast
cell- and T cell-dependent mechanism. 
 
J. Immunol
 
. 164:
2046–2052.
10. Gurish, M.F., W.S. Pear, R.L. Stevens, M.L. Scott, K. Sokol,
N. Ghildyal, M.J. Webster, X. Hu, K.F. Austen, D. Balti-
more, and D.S. Friend. 1995. Tissue-regulated differentiation
and maturation of a v-abl-immortalized mast cell-committed
progenitor. 
 
Immunity
 
. 3:1–20.
11. Friend, D.S., N. Ghildyal, K.F. Austen, M.F. Gurish, R.
Matsumoto, and R.L. Stevens. 1996. Mast cells that reside at
different locations in the jejunum of mice infected with
 
Trichinella spiralis
 
 exhibit sequential changes in their granule
ultrastructure and chymase phenotype. 
 
J. Cell Biol
 
. 135:279–
290.
12. Stevens, R.L., D.S. Friend, H.P. McNeil, V. Schiller, N.
Ghildyal, and K.F. Austen. 1994. Strain-specific and tissue-
specific expression of mouse mast cell secretory granule pro-
teases. 
 
Proc. Nat. Acad. Sci. USA
 
. 91:128–132.
13. Enerback, L. 1966. Mast cells in rat gastrointestinal mucosa.
II. Dye-binding and metachromatic properties. 
 
Acta. Pathol.
Microbiol. Scand
 
. 66:303–312.
14. Stevens, R.L., T.D. Lee, D.C. Seldin, K.F. Austen, A.D. Be-
fus, and J. Bienenstock. 1986. Intestinal mucosal mast cells
from rats infected with 
 
Nippostrongylus brasiliensis
 
 contain pro-
tease-resistant chondroitin sulfate di-B proteoglycans. 
 
J. Im-
munol. 
 
137:291–295.
15. Tantravahi, R.V., R.L. Stevens, K.F. Austen, and J.H. Weis.
1986. A single gene in mast cells encodes the core peptides of
heparin and chondroitin sulfate proteoglycans. 
 
Proc. Natl.
Acad. Sci. USA.
 
 83:9207–9210.
16. Stevens, R.L., C.C. Fox, L.M. Lichtenstein, and K.F. Aus-
ten. 1988. Identification of chondroitin sulfate E proteogly-
cans and heparin proteoglycans in the secretory granules of
human lung mast cells. 
 
Proc. Nat. Acad. Sci. USA
 
. 85:2284–
2287.
17. Ruitenberg, E.J., and A. Elgersma. 1976. Absence of intesti-
nal mast cell response in congenitally athymic mice during
 
Trichinella spiralis
 
 infection. 
 
Nature
 
. 264:258–260. 
F5
 
Gurish and Austen
18. Irani, A.M., S.S. Craig, G. DeBlois, C.O. Elson, N.M.
Schechter, and L.B. Schwartz. 1987. Deficiency of the
tryptase-positive, chymase-negative mast cell type in gas-
trointestinal mucosa of patients with defective T lymphocyte
function. 
 
J. Immunol
 
. 138:4381–4386.
19. Heavey, D.J., P.B. Ernst, R.L. Stevens, A.D. Befus, J. Bien-
enstock, and K.F. Austen. 1988. Generation of leukotriene
C
 
4
 
, leukotriene B
 
4
 
, and prostaglandin D
 
2
 
 by immunologically
activated rat intestinal mucosa mast cells. 
 
J. Immunol
 
. 140:
1953–1957.
20. Huang, C., A. Sali, and R.L. Stevens. 1998. Regulation and
function of mast cell proteases in inflammation. 
 
J. Clin. Im-
munol
 
. 18:169–183.
21. Li, L., D.E. Humphries, S.A. Krilis, and R.L. Stevens. 2000.
The role of mast cell-derived, preformed granule mediators
in embryonic development. 
 
FASEB J
 
. 14:A1128. (Abstr.)
22. Stevens, R.L., D. Qui, H.P. McNeil, D.S. Friend, J.E. Hunt,
K.F. Austen, and J. Zhang. 1996. Transgenic mice that pos-
sess a disrupted mast cell protease 5 (mMCP-5) gene cannot
store carboxypeptidase A in their granules. 
 
FASEB J. 
 
10:
1307. (Abstr.)
23. Humphries, D.E., G.W. Wong, D.S. Friend, M.F. Gurish,
W.T. Qiu, C. Huang, A.H. Sharpe, and R.L. Stevens. 1999.
Heparin is essential for the storage of specific granule pro-
teases in mast cells. 
 
Nature
 
. 400:769–772.
24. Huang, C., D.S. Friend, W.T. Qiu, G.W. Wong, G. Mo-
rales, J. Hunt, and R.L. Stevens.1998. Induction of a selec-
tive and persistent extravasation of neutrophils into the peri-
toneal cavity by tryptase mouse mast cell protease 6. 
 
J.
Immunol
 
. 160:1910–1919.
25. Huang, C., G.T. De Sanctis, P.J. O’Brien, J.P. Mizerd, D.S.
Friend, J.M. Drazen, L.F. Brass, and R.L. Stevens. 2001. Hu-
man mast cell tryptase betaI: evaluation of its substrate speci-
ficity and demonstration of its importance in bacterial infec-
tions of the lung. 
 
J. Biol. Chem
 
. In press.
26. He, S., and A.F. Walls. 1998. Human mast cell chymase in-
duces the accumulation of neutrophils, eosinophils and other
inflammatory cells in vivo. 
 
Br. J. Pharmacol
 
. 125:1491–1500.
27. He, S., Q. Peng, and A.F. Walls. 1997. Potent induction of a
neutrophil and eosinophil-rich infiltrate in vivo by human
mast cell tryptase: selective enhancement of eosinophil re-
cruitment by histamine. 
 
J. Immunol
 
. 159:6216–6225.
28. Huang, C., G.W. Wong, N. Ghildyal, M.F. Gurish, A. Sali,
R. Matsumoto, and R.L. Stevens. 1997. The tryptase, mouse
mast cell protease 7, degrades fibrinogen in V3-mastocytosis
mice
 
. J. Biol. Chem
 
. 272:31885–31893.
29. Knight, P.A., S.H. Wright, C.E. Lawrence, Y.Y. Paterson,
and H.R Miller. 2000. Delayed expulsion of the nematode
 
Trichinella spiralis
 
 in mice lacking the mucosal mast cell–spe-
cific granule chymase, mouse mast cell protease-1. 
 
J. Exp.
Med.
 
 192:1849–1856.
30. Lawrence, C.E., J.C. Paterson, L.M. Higgins, T.T. Mac-
Donald, M.W. Kennedy, and P. Garside. 1998. IL-4-regu-
lated enteropathy in an intestinal nematode infection. 
 
Eur. J.
Immunol
 
. 28:2672–2684.
31. Lantz, C.S., J. Boesiger, C.H. Song, N. Mach, T. Kobayashi,
R.C. Mulligan, Y. Nawa, G. Dranoff, and S.J. Galli. 1998.
Role for interleukin-3 in mast cell and basophil development
and in immunity to parasites. 
 
Nature.
 
 392:90–93
32. Coussens, L.M., W.W. Raymond, G. Bergers, M. Laig-
Webster, O. Behrendtsen, Z. Werb, G.H. Caughey, and D.
Hanahan. 1999. Inflammatory mast cells up-regulate angio-
genesis during squamous epithelial carcinogenesis. 
 
Genes Dev
 
.
13:1382–1397.
33. Kanaoka, Y., A. Maekawa, J.F. Penrose, K.F. Austen, and
B.K. Lam. 2001. Attenuated zymosan-induced peritoneal
vascular permeability and IgE-dependent passive cutaneous
anaphylaxis in mice lacking leukotriene C
 
4
 
 synthase. 
 
J. Biol.
Chem
 
. In press.
34. Matsuoka, T., M. Hirata, H. Tanaka, Y. Takahashi, T. Mu-
rata, K. Kabashima, Y. Sugimoto, T. Kobayashi, F. Ushikubi,
Y. Aze, et al. 2000. Prostaglandin D
 
2
 
 as a mediator of allergic
asthma. 
 
Science.
 
 287:2013–2017.
35. Hirai, H., K. Tanaka, O. Yoshie, K. Ogawa, K. Kenmotsu,
Y. Takamori, M. Ichimasa, K. Sugamura, M. Nakamura, S.
Takano, and K. Nagata. 2001. Prostaglandin D
 
2
 
 selectively
induces chemotaxis in T helper type 2 cells, eosinophils, and
basophils via seven-transmembrane receptor CRTH2. 
 
J. Exp.
Med.
 
 193:255–262.
36. Maurer, M., B. Echtenacher, L. Hültner, G. Kollias, D.N.
Männel, K.E. Langley, and S.J. Galli. 1998. The c-kit ligand,
stem cell factor, can enhance innate immunity through effects
on mast cells. 
 
J. Exp. Med
 
. 188:2343–2348.
37. Malaviya, R., T. Ikeda, E. Ross, and S.N. Abraham. 1996.
Mast cell modulation of neutrophil influx and bacterial clear-
ance at sites of infection through TNF-alpha. 
 
Nature
 
. 381:77–
80.
38. Walsh, L.J., G. Trinchieri, H.A. Waldorf, D. Whitaker, and
G.F. Murphy. 1991. Human dermal mast cells contain and
release tumor necrosis factor alpha, which induces endothelial
leukocyte adhesion molecule 1. 
 
Proc. Natl. Acad. Sci. USA
 
.
88:4220–4224.
39. Goldman, G., R. Welbourn, J.M. Klausner, L. Kobzik, C.R.
Valeri, D. Shepro, and H.B. Hechtman. 1992. Mast cells and
leukotrienes mediate neutrophil sequestration and lung
edema after remote ischemia in rodents. 
 
Surgery
 
. 112:578–
586.
40. Kyriakides, C., W.G. Austen, Jr., Y. Wang, J. Favuzza, F.D.
Moore, Jr., and H.B. Hechtman. 2000. Neutrophil mediated
remote organ injury after lower torso ischemia and reperfu-
sion is selectin and complement dependent
 
. J. Trauma
 
. 48:
32–38.
41. Mukundan, C., M.F. Gurish, K.F. Austen, H.B. Hechtman,
and D.S. Friend. 2001. Mast cell mediation of muscle and
pulmonary injury following hind limb ischemia-reperfusion.
 
J. Histochem. Cytochem
 
. In press.
42. James, Jr., L.P., and K.F. Austen. 1964. Fatal systemic ana-
phylaxis in man. 
 
N. Engl. J. Med
 
. 270:597–603.